|
Mar 17
|
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skippin...
|
|
Mar 12
|
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
|
|
Mar 1
|
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line
|
|
Feb 28
|
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
|
|
Feb 27
|
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
|
|
Jan 1
|
Why Is Avidity Biosciences, Inc. (RNA) Among the Best Multibagger Stocks to Buy Right Now?
|
|
Oct 18
|
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up
|
|
Sep 29
|
Is Avidity Biosciences, Inc. (RNA) the Best Performing Long Term Stock in 2024?
|
|
Sep 26
|
Is Avidity Biosciences Inc. (RNA) the Best Performing Small-Cap Stock in 2024?
|
|
Aug 5
|
Avidity Biosciences Announces Appointment of John B. Moriarty, Jr. as Chief Legal Officer
|
|
Jul 24
|
3 Stocks Doing Even Better Than Superstar Super Micro (SMCI)
|
|
Jun 20
|
Avidity Biosciences Partners with the FSHD Society to Raise Awareness of Facioscapulohumeral Muscular Dystrophy on World FSHD Day
|
|
Jun 19
|
Estimating The Intrinsic Value Of Avidity Biosciences, Inc. (NASDAQ:RNA)
|
|
Jun 14
|
Avidity Biosciences, Inc. Announces Pricing of Public Offering of Common Stock
|
|
Jun 13
|
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
|
|
Jun 12
|
The 'Impressive' Results That Sent Top 1% Avidity Biosciences To A Record
|
|
Jun 12
|
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
|
|
Jun 12
|
Avidity drug for muscular dystrophy shows promise; Syntis takes new approach to weight loss
|
|
Jun 12
|
Avidity Announces Unprecedented AOC 1020 Data from Phase 1/2 FORTITUDE™ Trial Demonstrating Greater Than 50 Percent Reduction in DUX4 Regulated Genes and Trends of Functional Improvement in People Living with Facioscapulohumeral Muscular Dystrophy
|
|
May 15
|
Avidity Biosciences Announces Appointment of Simona Skerjanec to Board of Directors
|